TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Antigenics Sees Encouraging Results; Good Long Term Pick VFC submits: It's been a long road for Antigenics (AGEN) since announcing that Russia had approved Oncophage for the treatment of kidney cancer in April of 2008, based on a subset of patients from a Phase III trial. Although the trial results were not thought to be encouraging enough to be brought before the US FDA, Antigenics applied for approval in Europe based on the same subset data that convinced Russia to approve, but were denied this time, sending the AGEN stock back to the sub-$1 level after having had an impressive run during 2009.After trading at those levels for most of 2010, AGEN had a bit of a bounce back of late, hitting as high as just over $1.70, although no significant news had been released to spur such a spike in price.Complete Story » seekingalpha.com |
EPA Focuses on Poor, Minorities The Environmental Protection Agency outlined a plan for placing special emphasis on the health of low-income and minority populations when drafting rules. online.wsj.com |
Adventrx Pharmaceuticals: Primed to Jump or Drop? Tony Pelz submits:I have been doing my monthly review of a couple hundred small-cap biotech companies and took a closer look at ADVENTRX Pharmaceuticals (ANX). According to the company’s website: ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. Its lead product candidates include ANX-530, an emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer and ANX-514, an emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.Complete Story » seekingalpha.com |
Novartis Prices New M.S. Drug Novartis said its new drug for multiple sclerosis will have a wholesale price of about $48,000 a year per person in the U.S., making it among the most expensive drugs for the disease. online.wsj.com |
PPD and VirtualScopics Establish Strategic Alliance for Medical Imaging Services [Business Wire] - PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies. us.rd.yahoo.com |